한글목차

세계 라임병 백신 시장 전망은 유망하며, 병원 및 임상실험실 시장에도 기회가 있습니다. 라임병 백신 시장은 2025-2031년 연평균 복합 성장률(CAGR) 8.1%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 신흥 매개 질환 증가, 정부의 이니셔티브와 이니셔티브의 확대, 공중 보건 교육 및 인식 제고 캠페인 증가입니다.

• Lucintel의 예측에 따르면, 기술별로는 민감도가 높고 적용 범위가 넓은 림프구 형질전환 검사가 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
• 최종 용도별로는 병원은 환자 수가 많고 다양한 서비스를 제공하기 때문에 더 높은 성장이 예상됩니다.
• 지역별로는 북미가 의료 선진국으로 인프라가 잘 갖추어져 있어 예측 기간 동안 가장 높은 성장이 예상됩니다.

라임병 백신 시장의 새로운 트렌드

라임병 백신 시장은 기술 발전부터 공중보건 전략의 변화까지 다양한 세계 트렌드에 따라 빠르게 발전하고 있습니다. 이러한 추세는 라임병 대응 방식을 재구성하고, 백신 개발자와 공중보건 기관에 새로운 기회를 제공합니다.

• 백신 연구개발에 재집중: 2002년 LYMErix의 철수 이후, 라임병 백신 개발에 다시 집중하고 있습니다. 연구자들은 mRNA, 재조합 DNA 등 첨단 기술을 이용한 새로운 백신 후보를 찾고 있습니다. 이 새로운 백신은 안전성 문제, 유효성 등 기존 후보물질의 단점을 극복하는 것을 목표로 하고 있습니다. 라임병의 발병률이 증가함에 따라 이러한 노력은 더욱 탄력을 받고 있으며, 여러 백신이 임상시험에 들어가고 있습니다. 이러한 추세는 라임병 대책의 장기적인 해결책에 대한 긍정적인 전환을 의미합니다.
• 매개체 감염병 백신에 대한 수요 증가: 기후 변화가 진드기의 서식 분포에 영향을 미치면서 라임병과 같은 매개체 감염을 예방하는 백신에 대한 수요가 증가하고 있습니다. 특히 라임병이 알려지지 않은 지역에서 진드기가 전 세계적으로 확산됨에 따라 백신 접종 전략에 대한 광범위한 요구가 발생하고 있습니다. 정부와 보건 기관은 라임병이 중요한 부분을 차지하는 더 광범위한 진드기 매개 질환에 주목하고 있습니다. 이러한 추세는 이러한 질병을 통제하고 새로운 지역에서의 대규모 발병을 예방하기 위한 백신의 시급성을 강조하고 있습니다.
• 세계 백신 공동개발: 제약사, 학계, 정부 간 공동연구는 라임병 백신 시장의 중요한 트렌드입니다. 라임병은 전 세계적으로 중요한 문제이기 때문에 조사 활동은 점점 더 국제적으로 이루어지고 있습니다. 미국, 독일 등 라임병 발병률이 높은 국가들은 지식, 자원, 임상시험 데이터를 공유하기 위해 협력하고 있습니다. 이러한 협력적 접근 방식은 백신 개발 및 유통을 촉진하고, 전 세계적으로 증가하는 라임병에 대한 보다 협력적인 대응을 보장하고 있습니다.
• 공중보건 교육 및 홍보 캠페인 공중보건 교육은 라임병 백신 프로그램의 성공에 필수적인 요소입니다. 라임병은 진단과 치료가 어렵기 때문에 교육 캠페인은 진드기 물림 예방, 라임병 증상, 백신 접종의 중요성에 대한 인식을 높이고 있습니다. 이 캠페인은 예방접종에 대한 거부감을 없애고 예방책의 중요성을 알리는 것을 목표로 하고 있습니다. 일반인의 인식이 높아짐에 따라 백신 접종률이 높아져 라임병 백신의 지속 가능한 시장 개척을 촉진할 것으로 기대됩니다.
• 라임병 백신의 정기 예방접종 프로그램 통합: 라임병 백신이 널리 보급되면, 정기 예방접종 프로그램에 통합하는 것이 중요한 추세가 될 것입니다. 이러한 통합을 통해 특히 라임병이 유행하는 지역에서는 백신 접종이 공중 보건 활동의 표준적인 일부가 될 것입니다. 라임병 백신이 소아기 예방접종 일정에 포함되면 접종률이 향상되고, 발병률이 감소할 수 있습니다. 이러한 추세는 라임병 예방의 확산과 백신 전략의 장기적인 성공에 매우 중요합니다.

이러한 새로운 추세는 백신 접종을 통한 라임병 예방에 대한 관심이 높아진 것을 반영하고 있습니다. 백신 개발의 기술적 진보, 일반 대중의 인식 개선, 세계 협력 체계에 이르기까지 이러한 추세는 라임병 백신 시장이 긍정적인 방향으로 나아가고 있음을 보여줍니다. 이러한 변화는 백신 개발을 가속화하고, 공중보건 성과를 개선하며, 전 세계 라임병의 부담을 줄일 수 있을 것으로 기대됩니다.

라임병 백신 시장의 최근 동향

라임병 백신 시장의 최근 동향은 예방 전략의 전망을 형성하고 있으며, 라임병 억제에 점점 더 초점을 맞추고 있음을 보여줍니다. 다음의 주요 발전은 현재 시장의 방향성을 잘 보여주고 있습니다.

• 새로운 라임병 백신 후보물질 개발: 여러 제약회사들이 새로운 라임병 백신 연구 단계에 들어갔으며, mRNA나 재조합 단백질과 같은 혁신적인 기술을 이용한 유망한 후보물질이 등장하고 있습니다. 이러한 백신은 안전성 개선, 효능 향상, 광범위한 방어를 목표로 하고 있습니다. 현재 여러 백신 후보들이 임상시험 단계에 있으며, 향후 몇년안에 새로운 백신의 물결이 밀려올 가능성을 보여주고 있습니다.
• 라임병 백신 연구 파트너십: 제약기업과 연구기관의 공동 개발은 라임병 백신 개발을 가속화하고 있습니다. 그 대표적인 예가 보다 효과적인 라임병 백신을 개발하기 위한 미국 기업과 학계의 협력입니다. 이러한 협력 관계는 더 나은 자원 배분과 신속한 백신 개발을 가능하게 하여 라임병 발병률을 낮추기 위한 전 세계적인 노력에 기여하고 있습니다.
• 라임병 백신 연구 자금 지원 확대: 미국, 독일 등 각국 정부는 진드기 매개 감염병으로 인한 공중보건 위협이 증가하고 있음을 인식하고 라임병 백신 연구에 대한 자금 지원을 확대하고 있습니다. 이 자금 지원은 임상시험과 새로운 백신 개발에 도움이 되고 있습니다. 라임병 환자가 증가함에 따라 백신 연구에 대한 자원 배분이 증가하여 효과적인 백신의 신속한 개발이 기대되고 있습니다.
• 전 세계적으로 라임병에 대한 인식이 높아짐: 라임병 환자가 이전에 감염자가 없었던 지역에서 라임병 환자가 증가함에 따라 라임병과 공중보건에 미치는 영향에 대한 인식이 높아지고 있습니다. 세계보건기구(WHO)와 CDC와 같은 기관은 진드기 매개 질환에 대한 인식을 높이고 라임병 백신에 대한 관심을 높이고 있습니다. 이러한 관심의 변화에 따라 예방책과 백신에 대한 수요도 증가하고 있습니다.
• 다중 진드기 매개 질환에 대한 백신 개발: 진드기 매개 질환 증가로 인해 여러 병원체를 표적으로 하는 백신 개발이 진행되고 있습니다. 라임병, 진드기 매개 뇌염, 기타 진드기 매개 질환을 예방할 수 있는 백신을 연구하는 기업도 있습니다. 이러한 다중 표적 백신은 다양한 진드기 매개 질환의 영향을 받는 지역의 공중 보건 활동을 개선하기 위해 종합적인 방어 가능성을 제공합니다.

라임병 백신 시장의 최근 동향은 백신 연구, 파트너십, 사회적 인식이 크게 발전하고 있음을 보여줍니다. 이러한 노력은 라임병 및 기타 진드기 매개 질환으로 인한 전 세계적인 부담을 줄이고, 예방에 대한 새로운 기회를 제공하며, 전 세계적으로 공중보건 성과를 향상시킬 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 라임병 백신 시장 : 기술별

• 개요
• 매력 분석 : 기술별
• 림프구 변형 검사 : 동향과 예측(2019-2031년)
• 소변 항원 검사 : 동향과 예측(2019-2031년)
• 면역 형광 염색 핵산 검사 : 동향과 예측(2019-2031년)
• 혈청학적 검사 : 동향과 예측(2019-2031년)

제5장 세계의 라임병 백신 시장 : 최종 용도별

• 개요
• 매력 분석 : 최종 용도별
• 병원 : 동향과 예측(2019-2031년)
• 임상 실험실 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031)

제6장 지역 분석

• 개요
• 세계의 라임병 백신 시장 : 지역별

제7장 북미의 라임병 백신 시장

• 개요
• 북미의 라임병 백신 시장 : 기술별
• 북미의 라임병 백신 시장 : 최종 용도별
• 미국의 라임병 백신 시장
• 멕시코의 라임병 백신 시장
• 캐나다의 라임병 백신 시장

제8장 유럽의 라임병 백신 시장

• 개요
• 유럽의 라임병 백신 시장 : 기술별
• 유럽의 라임병 백신 시장 : 최종 용도별
• 독일의 라임병 백신 시장
• 프랑스의 라임병 백신 시장
• 스페인의 라임병 백신 시장
• 이탈리아의 라임병 백신 시장
• 영국의 라임병 백신 시장

제9장 아시아태평양의 라임병 백신 시장

• 개요
• 아시아태평양의 라임병 백신 시장 : 기술별
• 아시아태평양의 라임병 백신 시장 : 최종 용도별
• 일본의 라임병 백신 시장
• 인도의 라임병 백신 시장
• 중국의 라임병 백신 시장
• 한국의 라임병 백신 시장
• 인도네시아의 라임병 백신 시장

제10장 기타 지역(ROW)의 라임병 백신 시장

• 개요
• 기타 지역(ROW)의 라임병 백신 시장 : 기술별
• 기타 지역(ROW)의 라임병 백신 시장 : 최종 용도별
• 중동의 라임병 백신 시장
• 남미의 라임병 백신 시장
• 아프리카의 라임병 백신 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 기술별
  • 성장 기회 : 최종 용도별
• 세계 라임병 백신 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 인수합병(M&A), 계약, 제휴 및 합작투자(JV)

제13장 밸류체인 주요 기업 개요

• Competitive Analysis
• T2 Biosystems
• Bio-Rad Laboratories
• Oxford Immunotec USA
• ROCHE DIAGNOSTICS INTERNATIONAL LTD
• Abbott

제14장 부록

• 그림 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global Lyme disease vaccine market looks promising with opportunities in the markets. The Lyme disease vaccine market is expected to grow with a CAGR of 8.1% from 2025 to 2031. The major drivers for this market are the increasing occurrences of emerging vector-borne diseases, the expanding government efforts and initiatives, and the increasing public health education and awareness campaigns.

• Lucintel forecasts that, within the technology category, lymphocytic transformation test is expected to witness higher growth over the forecast period due to higher sensitivity, broader applicability.
• Within the end-use category, hospitals are expected to witness higher growth due to larger patient volume, diverse services.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to advanced healthcare, strong infrastructure.

Emerging Trends in the Lyme Disease Vaccine Market

The Lyme disease vaccine market is evolving rapidly, driven by various global trends, from technological advancements to changes in public health strategies. These trends are reshaping how Lyme disease is addressed and providing new opportunities for vaccine developers and public health organizations.

• Renewed focus on vaccine research and development: After the withdrawal of LYMErix in 2002, there has been a renewed focus on Lyme disease vaccine development. Researchers are exploring new vaccine candidates using advanced technologies such as mRNA and recombinant DNA. These new vaccines aim to overcome the shortcomings of previous candidates, including safety concerns and efficacy. With increasing Lyme disease incidence, these efforts are gaining momentum, with multiple vaccines entering clinical trials. This trend signifies a positive shift toward long-term solutions in combating Lyme disease.
• Growing demand for vector-borne disease vaccines: As climate change influences the distribution of tick populations, the demand for vaccines to prevent vector-borne diseases like Lyme disease is increasing. The global spread of ticks, especially in areas not previously known for Lyme disease, has created a wider need for vaccination strategies. Governments and health organizations are focusing on the broader category of tick-borne diseases, of which Lyme disease is a significant part. This trend emphasizes the urgency for vaccines to control these diseases and prevent larger outbreaks in new areas.
• Collaborative global vaccine development: Collaboration between pharmaceutical companies, academic institutions, and governments is a key trend in the Lyme disease vaccine market. With Lyme disease being a significant global concern, research efforts are increasingly international. Countries with high Lyme disease rates, such as the United States and Germany, are working together to share knowledge, resources, and clinical trial data. This collaborative approach helps accelerate the development and distribution of vaccines, ensuring a more coordinated response to the global rise in Lyme disease.
• Public health education and awareness campaigns: Public health education is critical to the success of any Lyme disease vaccine program. With Lyme disease being difficult to diagnose and treat, educational campaigns are raising awareness about tick bite prevention, the symptoms of Lyme disease, and the importance of vaccination. These campaigns aim to address vaccine hesitancy and promote the importance of preventative measures. As public awareness grows, vaccine uptake is expected to rise, supporting the development of a sustainable market for Lyme disease vaccines.
• Integration of Lyme disease vaccines into routine immunization programs: Once a Lyme disease vaccine becomes widely available, integrating it into routine immunization programs is seen as a key trend. This integration would make vaccination a standard part of public health efforts, especially in areas where Lyme disease is prevalent. The inclusion of Lyme disease vaccines in childhood immunization schedules could increase coverage and reduce disease incidence. This trend is crucial for ensuring widespread protection and the long-term success of vaccine strategies.

These emerging trends reflect the growing focus on preventing Lyme disease through vaccination. From technological advancements in vaccine development to increased public awareness and global collaboration, these trends indicate that the Lyme disease vaccine market is on a positive trajectory. These shifts are expected to accelerate vaccine development, improve public health outcomes, and reduce the global burden of Lyme disease.

Recent Developments in the Lyme Disease Vaccine Market

Recent developments in the Lyme disease vaccine market are shaping the landscape of prevention strategies and are indicative of the increasing focus on controlling the disease. The following key developments highlight the current direction of the market.

• Advancement of new Lyme disease vaccine candidates: Several pharmaceutical companies have entered the research phase for new Lyme disease vaccines, with promising candidates using innovative technologies like mRNA and recombinant proteins. These vaccines aim to offer improved safety profiles, greater efficacy, and broader protection. Multiple vaccine candidates are currently in clinical trials, signaling the potential for a new wave of vaccines in the coming years.
• Lyme disease vaccine research partnerships: Collaboration between pharmaceutical companies and research institutions is accelerating Lyme disease vaccine development. A notable example is the partnership between U.S.-based companies and academic institutions to develop more effective Lyme disease vaccines. These collaborations allow for better resource allocation and faster vaccine development, contributing to global efforts to reduce Lyme disease incidence.
• Expanded funding for Lyme disease vaccine research: Governments in countries like the United States and Germany have increased funding for Lyme disease vaccine research, recognizing the growing public health threat posed by tick-borne diseases. This funding is helping support clinical trials and the development of new vaccines. As Lyme disease cases rise, the allocation of resources to vaccine research is expected to grow, ensuring the swift development of effective vaccines.
• Increased global awareness of Lyme disease: The rising number of Lyme disease cases in previously unaffected regions has led to increased awareness of the disease and its impact on public health. Organizations like the World Health Organization (WHO) and the CDC are promoting tick-borne disease awareness, which has generated interest in Lyme disease vaccines. This shift in focus has also increased the demand for prevention measures and vaccines.
• Development of vaccines for multiple tick-borne diseases: The increasing number of tick-borne diseases has led to the development of vaccines targeting multiple pathogens. Some companies are researching vaccines that can protect against Lyme disease, tick-borne encephalitis, and other tick-borne illnesses. These multi-target vaccines offer the potential for comprehensive protection, improving public health efforts in areas affected by various tick-borne diseases.

Recent developments in the Lyme disease vaccine market show significant progress in vaccine research, partnerships, and public awareness. These efforts are expected to reduce the global burden of Lyme disease and other tick-borne illnesses, offering new opportunities for prevention and improving public health outcomes worldwide.

Strategic Growth Opportunities in the Lyme Disease Vaccine Market

The Lyme disease vaccine market presents multiple strategic growth opportunities across various applications. These opportunities are expected to drive innovation, improve vaccine access, and contribute to the overall reduction of Lyme disease cases globally.

• Expanding vaccine access in endemic regions: There is a major opportunity to expand Lyme disease vaccine access in areas with high tick populations, such as the northeastern United States and parts of Europe. Government-backed programs and partnerships with healthcare providers can help ensure that vaccines reach at-risk populations, particularly in rural and underserved areas. Increasing access to vaccines will be key to controlling the spread of Lyme disease.
• Collaboration with public health organizations: Collaborating with global health organizations like the WHO and the CDC can accelerate vaccine distribution and implementation. These partnerships can help streamline regulatory approval processes and ensure vaccines are available in countries with the highest burden of Lyme disease. Collaboration can also facilitate the sharing of research and clinical data to improve vaccine efficacy and safety.
• Incorporation of Lyme disease vaccines in travel health: With increasing international travel, there is an opportunity to integrate Lyme disease vaccines into travel health programs, particularly for individuals traveling to areas with a high prevalence of Lyme disease. This would help prevent the spread of the disease to new regions and protect travelers from infection.
• Development of combination vaccines: The development of combination vaccines that protect against multiple tick-borne diseases, such as Lyme disease, tick-borne encephalitis, and babesiosis, is a growing opportunity. This would streamline vaccination schedules and increase vaccine uptake, providing comprehensive protection against tick-borne diseases.
• Focus on pediatric vaccination programs: Implementing Lyme disease vaccines into routine pediatric immunization schedules offers a significant growth opportunity. As Lyme disease affects children in many endemic areas, vaccinating children at an early age would be an effective prevention strategy, ensuring long-term protection and reducing the disease burden in younger populations.

The Lyme disease vaccine market holds significant growth opportunities, ranging from expanding access in endemic regions to developing combination vaccines. By addressing these opportunities, stakeholders can improve vaccine access, reduce the global impact of Lyme disease, and ensure better public health outcomes.

Lyme Disease Vaccine Market Driver and Challenges

The Lyme disease vaccine market is influenced by several key drivers and challenges, which include technological advancements, economic factors, and regulatory hurdles. These factors play a crucial role in shaping the development, approval, and distribution of Lyme disease vaccines. Technological innovation, particularly in vaccine development, has significantly advanced over recent years. However, challenges related to vaccine acceptance, regulatory approval processes, and economic considerations remain substantial. As the market continues to evolve, understanding these drivers and challenges is essential for shaping strategies to improve vaccine access, effectiveness, and distribution.

The factors responsible for driving the Lyme disease vaccine market include:

1. Rising incidence of Lyme disease: The increasing number of Lyme disease cases, particularly in regions where it was previously less common, is a major driver for the Lyme disease vaccine market. As more individuals are affected by the disease, there is heightened awareness of the need for preventive measures. The rising incidence is particularly evident in the United States and Europe, where tick populations have expanded due to climate change. This growing public health concern underscores the need for vaccines that can reduce the burden of Lyme disease and limit the spread of the disease, driving demand for vaccine development.

2. Technological advancements in vaccine development: Recent technological innovations in vaccine research, such as mRNA technology and recombinant DNA technology, have made the development of Lyme disease vaccines more feasible and efficient. These advanced technologies offer improved safety profiles and higher efficacy rates compared to previous vaccine candidates. With these advancements, the Lyme disease vaccine market has gained momentum, as pharmaceutical companies are able to create more effective vaccines. Additionally, the ability to rapidly adapt to emerging disease variants through mRNA vaccines can provide quicker responses to Lyme disease outbreaks, further fueling market growth.

3. Increased public and government awareness: Governments and public health organizations are increasingly recognizing Lyme disease as a significant threat, leading to greater investments in prevention and vaccine research. In countries like the U.S. and Germany, the CDC and other health agencies have launched educational campaigns about Lyme disease, increasing awareness and driving demand for vaccines. As awareness rises, public support for vaccination programs also grows, making it easier for companies to gain funding and approval for their vaccine candidates. This trend is essential for ensuring the availability and widespread adoption of Lyme disease vaccines.

4. Advancements in tick-borne disease research: The growing body of research into tick-borne diseases and their mechanisms has led to better understanding of Lyme disease and how it can be prevented. As research advances, the development of multi-pathogen vaccines that target not just Lyme disease but other tick-borne diseases, such as babesiosis and anaplasmosis, becomes more viable. This research-focused environment encourages the development of innovative vaccines, attracting more funding and scientific attention to the Lyme disease vaccine market, further accelerating progress in vaccine development.

5. Public health policy and infrastructure investment: Increased investments by governments into public health infrastructure, particularly in areas with high Lyme disease prevalence, support the growth of the vaccine market. As healthcare systems focus on preventive care, Lyme disease vaccines are seen as a critical tool in reducing healthcare costs associated with treating Lyme disease. Government funding, combined with expanded healthcare access, creates an environment conducive to the development and distribution of vaccines. This trend is expected to continue as policymakers prioritize disease prevention and seek to reduce the long-term healthcare burden.

Challenges in the Lyme Disease Vaccine Market are:

1. Vaccine hesitancy and acceptance: One of the major challenges facing the Lyme disease vaccine market is vaccine hesitancy, which is influenced by public skepticism, misinformation, and concerns about vaccine safety. Despite the growing awareness of Lyme disease, many individuals are still hesitant to receive the vaccine due to fear of side effects or mistrust of pharmaceutical companies. Overcoming this hesitancy will require extensive public education campaigns to highlight the benefits of vaccination and address concerns. Failure to address vaccine hesitancy could limit the effectiveness and adoption of Lyme disease vaccines.

2. Regulatory hurdles and approval delays: The process of obtaining regulatory approval for new vaccines is lengthy and complex, which presents a significant challenge for the Lyme disease vaccine market. Stringent safety and efficacy standards must be met, and extensive clinical trials are required, which can delay the availability of vaccines. In addition, varying regulatory standards across different countries add complexity to the approval process. Delays in approval can slow down the widespread adoption of Lyme disease vaccines, limiting their impact on public health in the short term.

3. High development and production costs: The costs associated with developing and producing Lyme disease vaccines can be prohibitively high. Vaccine development requires significant investment in research, clinical trials, and manufacturing, which can deter smaller companies from entering the market. Additionally, scaling up production to meet demand requires considerable resources. The high costs may limit the availability of the vaccine in low-income regions, further exacerbating health disparities. Overcoming these economic challenges is critical to ensuring that Lyme disease vaccines are accessible to all populations, particularly in endemic areas.

The Lyme disease vaccine market is shaped by a mix of drivers and challenges. While rising disease incidence, technological advancements, and increasing public awareness are fueling growth, challenges such as vaccine hesitancy, regulatory hurdles, and high development costs threaten to slow progress. The success of this market will depend on overcoming these obstacles through effective public health strategies, efficient regulatory processes, and investments in vaccine production. By addressing these challenges and leveraging the market drivers, the Lyme disease vaccine market can play a key role in preventing the spread of Lyme disease and improving global health outcomes.

List of Lyme Disease Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, Lyme disease vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Lyme disease vaccine companies profiled in this report include:

• T2 Biosystems
• Bio-Rad Laboratories
• Oxford Immunotec USA
• ROCHE DIAGNOSTICS INTERNATIONAL LTD
• Abbott

Lyme Disease Vaccine Market by Segment

The study includes a forecast for the global Lyme disease vaccine market by technology, end use, and region.

Lyme Disease Vaccine Market by Technology [Value from 2019 to 2031]:

• Lymphocytic Transformation Test
• Urine Antigen Testing
• Immunofluorescent Staining Nucleic Acid Test
• Serological Test

Lyme Disease Vaccine Market by End Use [Value from 2019 to 2031]:

• Hospitals
• Clinical Laboratories
• Others

Lyme Disease Vaccine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lyme Disease Vaccine Market

The Lyme disease vaccine market has seen increasing attention due to the rising incidence of Lyme disease, which is transmitted through tick bites and can lead to serious health issues if left untreated. Recent developments in this market across key countries, including the United States, China, Germany, India, and Japan, have been driven by both the increasing awareness of Lyme disease and advancements in vaccine research. These regions are witnessing significant progress in vaccine development, approval, and distribution, aiming to combat the disease more effectively and ensure better protection for populations at risk.

• United States: In the United States, Lyme disease remains a significant public health concern, particularly in the northeastern and upper midwestern regions. Recent developments include the ongoing research and potential reintroduction of Lyme disease vaccines, following the withdrawal of LYMErix in the early 2000s. With the rise in Lyme disease cases, both public and private entities are investing in vaccine research, with promising candidates currently in clinical trials. Additionally, the CDC has ramped up its educational campaigns regarding tick-borne diseases, and efforts to address vaccine hesitancy have grown as part of broader public health initiatives.
• China: In China, Lyme disease is increasingly recognized as an emerging infectious disease, particularly in rural areas where people are more likely to come into contact with ticks. The Chinese government has begun funding research into Lyme disease vaccines, and initial studies are showing promise. China's focus on public health infrastructure and the growing awareness of zoonotic diseases have led to increased investments in tick control and Lyme disease prevention. Additionally, Chinese pharmaceutical companies are working on domestic vaccine production to address this growing health threat, although widespread vaccine distribution is still in the early stages.
• Germany: Germany has seen steady advancements in the Lyme disease vaccine market, although there has not yet been a significant push for a national vaccine rollout. Lyme disease cases in Germany have risen, especially in the southern and eastern regions. The country has increased its investment in Lyme disease research, with efforts focused on understanding the full range of symptoms and the efficacy of potential vaccines. While Germany does not yet have an approved Lyme disease vaccine, there is considerable interest in collaboration with European Union research initiatives to develop and distribute a vaccine in the future.
• India: India has been facing an increasing incidence of vector-borne diseases, including Lyme disease, due to expanding tick populations. Research into vaccines for Lyme disease is in its early stages, with most efforts concentrated in academic and research institutions. India's government has been focusing on controlling tick-borne diseases more generally, which includes exploring vaccines for Lyme disease. While vaccine development has not yet reached the commercial stage, the growing recognition of Lyme disease and its health implications is expected to drive further research and development efforts in the coming years.
• Japan: Japan has a low but increasing number of Lyme disease cases, mainly in rural areas where tick populations are more prominent. Japanese health authorities have initiated research into Lyme disease vaccines as part of broader efforts to combat vector-borne diseases. Japan's highly advanced healthcare infrastructure and strong pharmaceutical industry place it in a favorable position to develop and distribute a Lyme disease vaccine. However, there is still a need for greater public awareness of Lyme disease and its prevention to increase vaccine acceptance once available. Research and collaboration with global health organizations are seen as key to future vaccine success.

Features of the Global Lyme Disease Vaccine Market

• Market Size Estimates: Lyme disease vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Lyme disease vaccine market size by technology, end use, and region in terms of value ($B).
• Regional Analysis: Lyme disease vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different technology, end use, and regions for the Lyme disease vaccine market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the Lyme disease vaccine market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Lyme disease vaccine market by technology (lymphocytic transformation test, urine antigen testing, immunofluorescent staining nucleic acid test, and serological test), end use (hospitals, clinical laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Lyme Disease Vaccine Market by Technology

• 4.1 Overview
• 4.2 Attractiveness Analysis by Technology
• 4.3 Lymphocytic Transformation Test: Trends and Forecast (2019-2031)
• 4.4 Urine Antigen Testing: Trends and Forecast (2019-2031)
• 4.5 Immunofluorescent Staining Nucleic acid Test: Trends and Forecast (2019-2031)
• 4.6 Serological Test: Trends and Forecast (2019-2031)

5. Global Lyme Disease Vaccine Market by End Use

• 5.1 Overview
• 5.2 Attractiveness Analysis by End Use
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Clinical Laboratories: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Lyme Disease Vaccine Market by Region

7. North American Lyme Disease Vaccine Market

• 7.1 Overview
• 7.2 North American Lyme Disease Vaccine Market by Technology
• 7.3 North American Lyme Disease Vaccine Market by End Use
• 7.4 United States Lyme Disease Vaccine Market
• 7.5 Mexican Lyme Disease Vaccine Market
• 7.6 Canadian Lyme Disease Vaccine Market

8. European Lyme Disease Vaccine Market

• 8.1 Overview
• 8.2 European Lyme Disease Vaccine Market by Technology
• 8.3 European Lyme Disease Vaccine Market by End Use
• 8.4 German Lyme Disease Vaccine Market
• 8.5 French Lyme Disease Vaccine Market
• 8.6 Spanish Lyme Disease Vaccine Market
• 8.7 Italian Lyme Disease Vaccine Market
• 8.8 United Kingdom Lyme Disease Vaccine Market

9. APAC Lyme Disease Vaccine Market

• 9.1 Overview
• 9.2 APAC Lyme Disease Vaccine Market by Technology
• 9.3 APAC Lyme Disease Vaccine Market by End Use
• 9.4 Japanese Lyme Disease Vaccine Market
• 9.5 Indian Lyme Disease Vaccine Market
• 9.6 Chinese Lyme Disease Vaccine Market
• 9.7 South Korean Lyme Disease Vaccine Market
• 9.8 Indonesian Lyme Disease Vaccine Market

10. ROW Lyme Disease Vaccine Market

• 10.1 Overview
• 10.2 ROW Lyme Disease Vaccine Market by Technology
• 10.3 ROW Lyme Disease Vaccine Market by End Use
• 10.4 Middle Eastern Lyme Disease Vaccine Market
• 10.5 South American Lyme Disease Vaccine Market
• 10.6 African Lyme Disease Vaccine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Technology
  • 12.2.2 Growth Opportunities by End Use
• 12.3 Emerging Trends in the Global Lyme Disease Vaccine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 T2 Biosystems
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bio-Rad Laboratories
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Oxford Immunotec USA
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 ROCHE DIAGNOSTICS INTERNATIONAL LTD
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Abbott
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us